Milataxel Completed Phase 2 Trials for Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00063219Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy